We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Combined With Infrared Imaging Automatically Classifies Tumors

By LabMedica International staff writers
Posted on 15 Feb 2023
Print article
Image: AI with infrared imaging enables precise colon cancer diagnostics (Photo courtesy of Pexels)
Image: AI with infrared imaging enables precise colon cancer diagnostics (Photo courtesy of Pexels)

In recent years, there has been a massive advancement in the available treatments for colon cancer. To ensure these therapies, such as immunotherapies, are effective, it is important to accurately diagnose the individual patient to provide specifically tailored treatment. Now, researchers have paired artificial intelligence (AI) with infrared (IR) imaging to develop an automated and precise method for diagnosing colon cancer and tailoring treatments to the patient. This label-free and automated technique complements existing methods for analyzing tissue samples.

Over the course of the past several years, a research team at the Centre for Protein Diagnostics (PRODI) at Ruhr University Bochum (Bochum, Germany) has been working on creating a new digital imaging method known as label-free IR imaging. This method measures the genomic and proteomic composition of the examined tissue, providing molecular information based on the infrared spectra. The information is then decoded using AI and displayed as false-color images utilizing image analysis methods from the field of deep learning.

The PRODI team successfully demonstrated that using deep neural networks, it was possible to effectively determine the microsatellite status, a prognostically and therapeutically relevant parameter, in colon cancer. In this process, the tissue sample passes through a standardized, user-independent, automated process and allows for spatially resolved differential classification of the tumor within an hour. On the other hand, classical diagnostics is used to determine the microsatellite status either through complex immunostaining of various proteins or via DNA analysis.

The ever-improving therapy options have made fast and uncomplicated determination of such biomarkers extremely important. Based on IR microscopic data, the researchers modified, optimized, and trained neuronal networks to establish label-free diagnostics. In contrast to immunostaining, the new approach does not need dyes and is much faster than DNA analysis.

“We were able to show that the accuracy of IR imaging for determining microsatellite status comes close to the most common method used in the clinic, immunostaining,” said PhD student Stephanie Schörner.

Related Links:
Ruhr University Bochum 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The utilization of liquid biopsies in cancer research is a rapidly developing field (Photo courtesy of Lightspring/Shutterstock)

Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis

B-cell lymphoma is the predominant form of cancer affecting the lymphatic system, with about 30% of patients with aggressive forms of this disease experiencing relapse. Currently, the disease’s risk assessment... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more